Roche

liver
Biotech

Roche becomes MASH player via $3.5B deal for 89bio, ph. 3 drug

Roche dived into the MASH space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate.
James Waldron Sep 18, 2025 5:02am
Two fencers spar in a stadium

Eye disease biotech launches with $100M, Roche rival in clinic

Sep 17, 2025 6:30am
follow the leader arrow growth crowd

CatalYm C-suite shake-up sees 4 new faces, 3 departures

Sep 15, 2025 10:53am
closed shuttered shut down closed

Sanofi becomes latest pharma to hold fire on UK R&D investments

Sep 15, 2025 10:14am
An arrow incrementally going up stairs before pointing straight up Blue background

BioNTech's ADC beats Roche’s Kadcyla in breast cancer phase 3

Sep 5, 2025 7:30am
IBD UC CD

Genentech pens $420M deal for Omass' preclinical IBD program

Sep 2, 2025 3:00am